Anavex Life Sciences Corp (AVXL)

[nidan7500]

Anavex previously reported interim data of the PART A intensive PK sub-cohort in the first 6 patients of the U.S. Phase 2 Rett syndrome study in which ANAVEX®2-73 (blarcamesine) demonstrated significant improvements of the two global efficacy endpoints, the Rett Syndrome Behaviour Questionnaire (RSBQ) Total score and the Clinical Global Impression – Improvement (CGI-I). ANAVEX®2-73 (blarcamesine) also significantly improved the RSBQ Hand Behaviours and the RSBQ Breathing Abnormalities. In addition, efficacy signals on both caregiver- and clinician-based measures of severity correlated with levels of glutamate, a key biomarker of disease pathogenesis.

Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial

PR june 16, 2020

Looks like the exceeding enrollment may be tied w/significant improvements noted earlier. RETT is a small, well organized-informed group. They know a good thing when they see one.